Stay updated on Pembrolizumab for Leptomeningeal Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Leptomeningeal Disease Clinical Trial page.

Latest updates to the Pembrolizumab for Leptomeningeal Disease Clinical Trial page
- Check5 days agoChange DetectedThe page now displays a new revision label Revision: v3.6.4, and the previous Revision: v3.6.3 label has been removed. This indicates a small internal update to the page versioning, not changes to the study details or user-facing content.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe page now shows Revision: v3.6.3, indicating a small deployment update.SummaryDifference0.1%

- Check34 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a newer version of the page; the previous revision tag was removed to reflect the update.SummaryDifference0.1%

- Check48 days agoChange DetectedNew navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment status message 'No longer looking for participants' now appears on the page. The label for Intervention/Treatment was standardized, and the revision tag was updated from v3.5.5 to v3.6.0.SummaryDifference0.6%

- Check55 days agoChange DetectedThe ClinicalTrials.gov entry version was updated from v3.5.4 to v3.5.5, indicating a new revision of the study record. This reflects a version update, typically for minor edits or corrections, not a change to study design or outcomes.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page's revision entry now shows Revision: v3.5.4 as the current version, replacing the previous Revision: v3.5.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Leptomeningeal Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Leptomeningeal Disease Clinical Trial page.